May 23, 2016 — Mobius Medical Systems announced today they have received clearance from the U.S. Food and Drug Administration (FDA) to market and accept orders for the new cone beam computed tomography (CBCT) module in Mobius3D.
The CBCT module is an online tool for evaluating patient positioning and patient anatomy changes. Within 60 seconds of performing a cone-beam CT of the patient and performing recommended shifts, Mobius3D reports a quantitative density gamma metric. Clinicians can use this metric to decide whether to proceed to treatment or not. The module can reveal incorrect shifts, changes in patient anatomy such as weight loss or even incorrect bolus placement. Once patient position is verified, Mobius3D then calculates in vivo 3-D dose for each treatment by using the measured log file data from the accelerator.
For more information: www.mobiusmed.com